-
Genting Xinyao and Tencent reach a strategic cooperation to create an innovative patient management service platform
Time of Update: 2021-08-01
This strategic cooperation, Tencent hopes to play a role in cloud computing, The technical advantages of data and artificial intelligence are fully integrated with the medical industry to provide more efficient services and management models for all parties in the medical and health ecosystem, and improve the level of patient health management .
-
Disinfection and Induction Control Academic Summit Forum under the New Situation of Normal Epidemic Prevention and Control and 2021 Shenzhen International Medical Disinfection and Induction Control Equipment Exhibition
Time of Update: 2021-08-01
Medical Network, July 22, by the Disinfection Industry Branch of the National Health Industry Enterprise Management Association, the Disinfection Professional Committee of the Shanghai Preventive Med
-
Mike Biology: 2 test kits obtained product registration certificate
Time of Update: 2021-07-31
25-hydroxyvitamin D determination kit (direct chemiluminescence method): used to quantitatively determine the concentration of 25-hydroxyvitamin D in human serum samples in vitro .
2. Human epididymal protein 4 determination kit (direct chemiluminescence method): used for in vitro quantitative determination of human epididymal protein 4 antigen content in human serum or plasma samples .
-
Gold-absorbing target next one-CD137 to see how pharmaceutical giants set off an upsurge in research and development
Time of Update: 2021-07-30
Studies have shown that ADG106 shows good safety characteristics and preliminary anti-tumor activity: after a patient with non-Hodgkin’s lymphoma who had failed multi-line therapy received ADG106, the tumor burden of two of the six target lesions was reduced More than 50%; in addition, in many patients, potential biological activity and pharmacodynamic biomarker responses were also observed, including related changes in the expression of 4-1BB .
-
$2.4 billion!
Time of Update: 2021-07-30
On July 22, Pfizer and Arvinas jointly announced an agreement to jointly develop and promote the oral PROTAC protein degrading agent ARV-471 that targets the estrogen receptor (ER) under research .
-
DNL310 lost in the warm-up match
Time of Update: 2021-07-30
news Today, the American biotechnology company Delani announced some patient data for its Hunter syndrome (also known as MPS II) drug DNL310 Phase I clinical trial .
In addition to enzyme replacement therapy, Sangamo's in vivo gene editing therapy SB-913 also reduced the levels of metabolic biomarkers in two patients.
-
Regeneron and AstraZeneca jointly develop weight-loss drugs
Time of Update: 2021-07-30
[News event]: Today, Regeneron and AstraZeneca announced that they will jointly develop GPR75 antagonists as a new type of weight-loss drug.
-
Weili Medical Deploys New Micro Nebulizer, "Chapter Encounter" Inhaled Vaccine Is About To Be Available
Time of Update: 2021-07-30
The inhaled vaccine requires a micro atomization design of "one-fifth the dose of the injection vaccine" (Academician Chen Wei), which uses magnetostrictive high-frequency oscillation technology, which is completely different from traditional atomizers.
-
Takeda Recombinant Von Willebrand Factor Phase 3 Clinical Reached Primary Endpoint
Time of Update: 2021-07-28
The results showed that during the 12-month study period: the use of rVWF preventive treatment in the previous on-demand treatment group can effectively reduce the annualized bleeding rate (sABR) of spontaneous and therapeutic bleeding events, and switch from pdVWF preventive treatment to rVWF Patients in the prophylactic treatment switch group maintained the same level of hemostasis control .
-
Shenzhen International Medical Equipment Exhibition will be held on August 18
Time of Update: 2021-07-27
In Vitro Diagnosis Area: In Vitro Diagnosis is an important detection technology to protect human health, and it is also one of the sub-sectors with broad development prospects in the current medical industry in my country.
Enterprise Enterprise Enterprise Exhibition Exhibition Exhibition Home health care area: At present, sub-health is the focus of the family medical industry.
-
Yuandong Bio-Paricalcitol Injection Passed Consistency Evaluation
Time of Update: 2021-07-27
On July 23, Yuandong Biological issued an announcement stating that it had recently received the "Drug Supplementary Application Approval Notice" for the chemical drug "Paricalcitol Injection" approved and issued by the State Food and Drug Administration.
-
Low-throughput screening finds anti-malarial drug candidates
Time of Update: 2021-07-27
New drug discovery usually starts with high-throughput screening, but if there is no suitable molecular framework in the screening library, just increasing the number of compounds will not increase the probability of finding a lead .
-
2021 Shenzhen International Dental Equipment and Materials Exhibition will be held in Shenzhen in August
Time of Update: 2021-07-27
You can visit this exhibition as long as you are customers in the following industries: Hospitals, dental hospitals, private dental hospitals, dental clinics, dentists, community health centers, distributors, agents , channel providers, electricity providers, retail outlets, oral medical colleges, dental professors, specialists, pharmacies , pharmaceutical chain, Large supermarkets, department stores, specialty stores, import and export companies, trading companies and other fields .
-
Huaren Pharmaceutical's subsidiary plans to acquire 100% equity of Hengjuxing Pharmaceutical for 800 million yuan
Time of Update: 2021-07-27
( (Referred to as "Hengjuxing Pharmaceutical", "target company") 100% equity, and indirectly holds 100% equity of Stellar Pharmaceuticals .
After the completion of this transaction, the company will hold 100% equity of Hengjuxing Pharmaceutical through its wholly-owned subsidiary, Qujiang Huaren, and indirectly hold 100% equity of Stellar Pharmaceuticals.
-
After 40 years of development, can the target P53 really not be a drug alone?
Time of Update: 2021-07-27
For another example, using a rational design method based on the p53 structure, it was found that the small molecule compounds PK083 and PK7080 can bind to the Y220C mutant, restore the WT conformation, and induce Y220C-dependent cell cycle arrest and apoptosis .
-
Benchmark Medical successfully completes $40 million in Series C financing
Time of Update: 2021-07-26
So far, the team of well-known domestic and foreign investors introduced by Benchmark Medical covers not only the leading biopharmaceutical companies WuXi AppTec and Jinyu Medical, but also the well-known domestic and foreign investment funds Northern Lights, Tonghe Yucheng, Scarlett Jianxin, Yuan Yi Capital, Arch Venture Partners, Aobo Capital, and WuXi Huiying have laid a solid foundation for benchmark healthcare to accelerate the registration and commercialization of early screening and early diagnosis products at home and abroad .
-
Gao Zhenkun, general manager of Beijing Tongrentang (Group) Company, under investigation
Time of Update: 2021-07-26
According to the Beijing Municipal Commission for Discipline Inspection: Gao Zhenkun, general manager of Beijing Tongrentang (Group) Co.
; In October 2014, he served as Deputy Secretary, Director and General Manager of the Party Committee of Beijing Tongrentang (Group) Co.
-
Shamrock Bio completed $230 million Series C financing and was overraised
Time of Update: 2021-07-26
This round of financing will support Shamrock Biology's application of its innovative and unique Trimer-Tag© (protein trimerization) technology platform to continue to develop and expand the R&D pipeline, including recombinant protein vaccines and tumor biological therapies .
-
The BCMA CAR-T jointly developed by Cinda Biotech and Reindeer Medical was approved as a breakthrough therapeutic drug by the State Drug Administration for the treatment of relapsed and refractory multiple myeloma
Time of Update: 2021-07-26
Cinda Biopharmaceuticals and Reindeer Medical jointly announced today that the fully human BCMA chimeric antigen receptor autologous T cell injection (Cinda Biologics R&D code: IBI326; Reindeer Medical R&D code: CT103A) jointly developed by both parties has passed the National Drug Supervision During the publicity period of the Center for Drug Evaluation (CDE) of the National Administration of Management (NMPA), the "breakthrough treatment drug variety" is included, and the proposed indication is relapsed/refractory multiple myeloma (R/R MM) .
-
Hengrui Medicine: Fluzoparib Capsules Obtained FDA International Multi-center Clinical Trial Qualification
Time of Update: 2021-07-26
After inquiry, fluzoparib currently has similar products Olaparib (trade name Lynparza), Rucaparib (trade name Rubraca), Niraparib (trade name Zejula) and Talazoparib (trade name Talzenna) have been approved for sale in the United States.
